About Ann DeWitt
Form D filings for Kano Therapeutics in 2024 list Ann DeWitt as director.
Ann DeWitt first appears on SEC filings in 2024.
Experience
This experience comes from SEC filings. The years are when the filings name Ann DeWitt in the role, so the role may have started earlier or lasted longer.
Key Colleagues at Startups
The people Ann DeWitt works with at each company, as listed on that company's latest Form D.
Kano Therapeutics Inc. · Form D, May 20, 2024
FE
Floris Engelhardt
Chief Executive Officer and director
JV
John Vroom
Director